{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:29:18Z","timestamp":1787509758245,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"am","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005897","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie et de Pathologie Sexuellement Transmissible","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006251","name":"University of Bordeaux","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006251","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.annder.2022.03.006","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T21:23:35Z","timestamp":1655933015000},"page":"222-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Alopecia areata: Recent advances and emerging therapies"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-0908","authenticated-orcid":false,"given":"J.","family":"Seneschal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Boniface","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jacquemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2022.03.006_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.annder.2022.03.006_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0200","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/jidsymp.2015.45","article-title":"Development of uniform protocol for alopecia areata clinical trials","volume":"17","author":"Solomon","year":"2015","journal-title":"J Invest Derm Symp P"},{"key":"10.1016\/j.annder.2022.03.006_bib0205","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.jaci.2019.08.035","article-title":"Frontiers in alopecia areata pathobiology research","volume":"144","author":"Gilhar","year":"2019","journal-title":"J Allergy Clin Immun"},{"key":"10.1016\/j.annder.2022.03.006_bib0210","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.annder.2022.03.006_bib0215","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/ncomms6966","article-title":"Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci","volume":"6","author":"Betz","year":"2015","journal-title":"Nature Commun"},{"key":"10.1016\/j.annder.2022.03.006_bib0220","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1038\/jidsymp.2013.5","article-title":"The genetic architecture of alopecia areata","volume":"16","author":"Petukhova","year":"2013","journal-title":"J Invest Derm Symp P"},{"key":"10.1016\/j.annder.2022.03.006_bib0225","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/jid.2012.129","article-title":"Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance","volume":"132","author":"Jagielska","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0230","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jisp.2017.10.014","article-title":"Hair follicle immune privilege revisited: the key to alopecia areata management","volume":"19","author":"Paus","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0235","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd1866","article-title":"Blockade of IL-7 signaling suppresses inflammatory responses and reverses alopecia areata in C3H\/HeJ mice","volume":"7","author":"Dai","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.annder.2022.03.006_bib0240","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.annder.2022.03.006_bib0245","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.4049\/jimmunol.1501798","article-title":"CXCR3 blockade inhibits t cell migration into the skin and prevents development of alopecia areata","volume":"197","author":"Dai","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.annder.2022.03.006_bib0250","first-page":"1277","article-title":"Alopecia areata profiling shows TH1","volume":"136","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing. J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2022.03.006_bib0255","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/exd.12918","article-title":"Biomarkers of alopecia areata disease activity and response to corticosteroid treatment","volume":"25","author":"Fuentes-Duculan","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0260","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jisp.2017.10.005","article-title":"Cytokine targeted therapeutics for\u00a0alopecia areata: lessons from\u00a0atopic dermatitis and other\u00a0inflammatory skin diseases","volume":"19","author":"Malik","year":"2018","journal-title":"J Invest Dermatol Symp Proceedings"},{"key":"10.1016\/j.annder.2022.03.006_bib0265","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/cup.13479","article-title":"Regulatory T-cells in alopecia areata","volume":"46","author":"Speiser","year":"2019","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.annder.2022.03.006_bib0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.05.002","article-title":"cells in skin facilitate epithelial stem cell differentiation","volume":"169","author":"Ali","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.annder.2022.03.006_bib0275","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","article-title":"The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata","volume":"83","author":"Meah","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0280","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaci.2015.11.001","article-title":"Extensive alopecia areata is reversed by IL-12\/IL-23p40 cytokine antagonism","volume":"137","author":"Guttman-Yassky","year":"2016","journal-title":"J Allergy Clin Immun"},{"key":"10.1016\/j.annder.2022.03.006_bib0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2019.08.014","article-title":"IL-12\/IL-23 neutralization is ineffective for alopecia areata in mice and humans","volume":"144","author":"Ortolan","year":"2019","journal-title":"J Allergy Clin Immun"},{"key":"10.1016\/j.annder.2022.03.006_bib0290","first-page":"534","article-title":"Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata","volume":"179","author":"Darrigade","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0295","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16493","article-title":"Alopecia areata development in atopic dermatitis patients treated with dupilumab","author":"St\u00e4nder","year":"2020","journal-title":"J Eur Acad Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0300","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16094","article-title":"Inflammatory alopecia in patients on dupilumab: a retrospective cohort study at an academic institution","volume":"34","author":"Zhu","year":"2020","journal-title":"J Eur Acad Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0305","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-IL-4R\u03b1) for alopecia areata patients","author":"Guttman-Yassky","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.annder.2022.03.006_bib0310","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote t-regulatory cells in alopecia areata","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0315","article-title":"Low dose IL-2 for treating moderate to severe alopecia areata. A 52 weeks multicenter prospective placebo-controlled study assessing its impact on T regulatory cells and natural killer populations","volume":"141","author":"Le Duff","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0320","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/09546634.2019.1592097","article-title":"The use of phosphodiesterase inhibitors for the treatment of alopecia","volume":"31","author":"Juh\u00e1sz","year":"2019","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.annder.2022.03.006_bib0325","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00403-018-1876-y","article-title":"A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata","volume":"311","author":"Mikhaylov","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.annder.2022.03.006_bib0330","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0335","article-title":"JAK inhibitors in dermatology: a comprehensive review","author":"Chapman","year":"2021","journal-title":"Part 1. J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0340","article-title":"JAK inhibitors in dermatology: a comprehensive review","author":"Chapman","year":"2021","journal-title":"Part 2. J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0345","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2022.03.006_bib0350","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0355","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaad.2019.10.016","article-title":"Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study","volume":"82","author":"Olsen","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2022.03.006_bib0360","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.annder.2022.03.006_bib0365","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.annder.2022.03.006_bib0370","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963822000382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963822000382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:10:19Z","timestamp":1758971419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963822000382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0151963822000382"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2022.03.006","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alopecia areata: Recent advances and emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2022.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}